Toll-like receptor 7 agonists and skin

Drug News and Perspectives

Volumn 21, Issue 3, 2008, Pages 158-165

  Novak, Natalija ^a   Yu, Chun Feng ^a   Bieber, Thomas ^a   Allam, Jean Pierre ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOKINE RECEPTOR ANTAGONIST; FLUOROURACIL; GUANINE NUCLEOTIDE; IMIDOAZOQUINOLINE DERIVATIVE; IMIQUIMOD; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR BLOCKING AGENT; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; PODOPHYLLIN; QUINOLINE DERIVATIVE; RNA; TOLL LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR ALPHA;

ACTINIC KERATOSIS; AGING; ALOPECIA; ALOPECIA TOTALIS; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIANGIOGENIC ACTIVITY; ANTIGEN PRESENTING CELL; APOPTOSIS; BASAL CELL CARCINOMA; BONE MARROW CELL; BOWEN DISEASE; BOWENOID PAPULOSIS; CAPILLARY MALFORMATION; CARCINOMA IN SITU; CLINICAL PRACTICE; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CONGENITAL BLOOD VESSEL MALFORMATION; CUTANEOUS T CELL LYMPHOMA; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISCOID LUPUS ERYTHEMATOSUS; DRUG EFFICACY; DRUG MECHANISM; DYSPLASTIC NEVUS; ENDOSOME; EPIDERMODYSPLASIA VERRUCIFORMIS; FLAKING; FLU LIKE SYNDROME; FOCAL EPITHELIUM HYPERPLASIA; HAILEY HAILEY DISEASE; HEADACHE; HEMANGIOMA; HERPES SIMPLEX; HUMAN; HYPOPIGMENTATION; IMMUNE RESPONSE; INNATE IMMUNITY; KAPOSI SARCOMA; KELOID; LEUKOPLAKIA; LYMPHATIC SYSTEM DISEASE; MALIGNANT LENTIGO; MELANOMA; MONOTHERAPY; MYALGIA; NONHUMAN; PHOTOAGING; PRECANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SKIN CRUSTING; SKIN DEFECT; SKIN DISEASE; SKIN EDEMA; SKIN EROSION; SKIN FLAKING; SKIN LEISHMANIASIS; SKIN METASTASIS; SKIN WEEPING; TH1 CELL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRAL SKIN DISEASE;

AMINOQUINOLINES; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; LIGANDS; SKIN DISEASES; SKIN DISEASES, VIRAL; SKIN NEOPLASMS; TOLL-LIKE RECEPTOR 7;

EID: 44949243141     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2008.21.3.1203412     Document Type: Review

References (111)

1. Janeway, C.A. Jr. and Medzhitov, R. Innate immune recognition. Annu Rev Immunol 2002, 20: 197-216.
2. Agrawal, S. and Kandimalla, E.R. Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem Soc Trans 2007, 35(Pt. 6): 1461-7.
3. Lasker, M.V. and Nair, S.K. Intracellular TLR signaling: A structural perspective on human disease. J Immunol 2006, 177(1): 11-6.
4. O'Neill, L.A., Fitzgerald, K.A. and Bowie, A.G. The Toll-IL-1 receptor adaptor family grows to five members. Trends Immunol 2003, 24(6): 286-90.
5. Wang, R.P., Zhang, M., Li, Y. et al. Differential regulation of IKKalpha-mediated activation of IRF3/7 by NIK. Mol Immunol 2008, 45(7): 1926-34.
6. Pirhonen, J., Siren, J., Julkunen, I. and Matikainen, S. IFN-alpha regulates Toll-like receptor-mediated IL-27 gene expression in human macrophages. J Leukoc Biol 2007, 82(5): 1185-92.
7. Mempel, M., Voelcker, V., Kollisch, G. et al. Toll-like receptor expression in human keratinocytes: Nuclear factor kappaB controlled gene activation by Staphylococcus aureus is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependent. J Invest Dermatol 2003, 121(6): 1389-96.
8. Jarrossay, D., Napolitani, G., Colonna, M., Sallusto, F. and Lanzavecchia, A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 2001, 31(11): 3388-93.
9. Heil, F., Hemmi, H., Hochrein, H. et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004, 303(5663): 1526-9.
10. Lee, J., Chuang, T.H., Redecke, V. et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7. Proc Natl Acad Sci U S A 2003, 100(11): 6646-51.
11. McInturff, J.E., Modlin, R.L. and Kim, J. The role of toll-like receptors in the pathogenesis and treatment of dermatological disease. J Invest Dermatol 2005, 125(1): 1-8.
12. Wenzel, J., Tormo, D. and Tuting, T. Toll-like receptor-agonists in the treatment of skin cancer: History, current developments and future prospects. In: Handbook of Experimental Pharmacology Vol. 183. Toll-Like Receptors (TLRs) and Innate Immunity. Bauer, S. and Hartmann, G. (Eds.). Springer: Heidelberg 2008, 201-20.
13. Miller, R.L., Gerster, J.F., Owens, M.L., Slade, H.B. and Tomai, M.A. Imiquimod applied topically: A novel immune response modifier and new class of drug. Int J Immunopharmacol 1999, 21(1): 1-14.
14. Harrison, C.J., Jenski, L., Voychehovski, T. and Bernstein, D.I. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antiviral Res 1988, 10(4-5): 209-23.
15. Dockrell, D.H. and Kinghorn, G.R. Imiquimod and resiquimod as novel immunomodulators. J Antimicrob Chemother 2001, 48(6): 751-5.
16. Torres, A., Storey, L., Anders, M. et al. Microarray analysis of aberrant gene expression in actinic keratosis: Effect of the Toll-like receptor-7 agonist imiquimod. Br J Dermatol 2007, 157(6): 1132-47.
17. Dummer, R., Urosevic, M., Kempf, W., Kazakov, D. and Burg, G. Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides. Dermatology 2003, 207(1): 116-8.
18. Wagner, T.L., Ahonen, C.L., Couture, A.M. et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol 1999, 191(1): 10-9.
19. Warger, T., Schild, H. and Rechtsteiner, G. Initiation of adaptive immune responses by transcutaneous immunization. Immunol Lett 2007, 109(1): 13-20.
20. Suzuki, H., Wang, B., Shivji, G.M. et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000, 114(1): 135-41.
21. Razafindratsita, A., Saint-Lu, N., Mascarell, L. et al. Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation. J Allergy Clin Immunol 2007, 120(2): 278-85.
22. Heib, V., Becker, M., Warger, T. et al. Mast cells are crucial for early inflammation, migration of Langerhans cells, and CTL responses following topical application of TLR7 ligand in mice. Blood 2007, 110(3): 946-53.
23. Arrese, J., Paquet, P., Claessens, N., Pierard-Franchimont, C. and Pierard, G. Dermal dendritic cells in anogenital warty lesions unresponsive to an immune-response modifier. J Cutan Pathol 2001, 28(3): 131-4.
24. Stary, G., Bangert, C., Tauber, M., Strohal, R., Kopp, T. and Stingl, G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med 2007, 204(6): 1441-51.
25. Ooi, T., Barnetson, R.S., Zhuang, L. et al. Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: A randomized controlled trial. Br J Dermatol 2006, 154(1): 72-8.
26. Urosevic, M., Dummer, R., Conrad, C. et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst 2005, 97(15): 1143-53.
27. Wuest, M., Dummer, R. and Urosevic, M. Induction of the members of Notch pathway in superficial basal cell carcinomas treated with imiquimod. Arch Dermatol Res 2007, 299(10): 493-8.
28. Arany, I., Tyring, S.K., Brysk, M.M. et al. Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (Imiquimod) in genital warts. Antimicrob Agents Chemother 2000, 44(7): 1869-73.
29. Schon, M., Bong, A.B., Drewniok, C. et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003, 95(15): 1138-49.
30. Lysa, B., Tartler, U., Wolf, R. et al. Gene expression in actinic keratoses: Pharmacological modulation by imiquimod. Br J Dermatol 2004, 151(6): 1150-9.
31. Smith, K., Hamza, S., Germain, M. and Skelton, H. Does imiquimod histologically rejuvenate ultraviolet radiation-damaged skin? Dermatol Surg 2007, 33(12): 1419-28.
32. Li, V.W., Li, W.W., Talcott, K.E. and Zhai, A.W. Imiquimod as an antiangiogenic agent. J Drugs Dermatol 2005, 4(6): 708-17.
33. Hesling, C., D'Incan, M., Mansard, S. et al. In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases. Br J Dermatol 2004, 150(4): 761-7.
34. Majewski, S., Marczak, M., Mlynarczyk, B., Benninghoff, B. and Jablonska, S. Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis. Int J Dermatol 2005, 44(1): 14-9.
35. Gencoglan, G., Karaca, S. and Ertekin, B. Angiolymphoid hyperplasia with eosinophilia successfully treated with imiquimod. A case report. Dermatology 2007, 215(3): 233-5.
36. Sidbury, R., Neuschler, N., Neuschler, E. et al. Topically applied imiquimod inhibits vascular tumor growth in vivo. J Invest Dermatol 2003, 121(5): 1205-9.
37. Smith, K., Hamza, S., Germain, M. and Skelton, H. Does imiquimod histologically rejuvenate ultraviolet radiation-damaged skin? Dermatol Surg 2007, 33(12): 1419-28.
38. Metcalf, S., Crowson, A.N., Naylor, M., Haque, R. and Cornelison, R. Imiquimod as an antiaging agent. J Am Acad Dermatol 2007, 56(3): 422-5.
39. Barland, C.O., Zettersten, E., Brown, B.S., Ye, J., Elias, P.M. and Ghadially, R. Imiquimod-induced interleukin-1 alpha stimulation improves barrier homeostasis in aged murine epidermis. J Invest Dermatol 2004, 122(2): 330-6.
40. Hadley, G., Derry, S. and Moore, R.A. Imiquimod for actinic keratosis: Systematic review and meta-analysis. J Invest Dermatol 2006, 126(6): 1251-5.
41. Schott, E., Witt, H., Neumann, K. et al. Association of TLR7 single nucleotide polymorphisms with chronic HCV-infection and response to interferon-a-based therapy. J Viral Hepat 2008, 15(1): 71-8.
42. Beutner, K.R., Tyring, S.K., Trofatter, K.F. Jr. et al. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother 1998, 42(4): 789-94.
43. Beutner, K.R., Spruance, S.L., Hougham, A.J., Fox, T.L., Owens, M.L. and Douglas, J.M. Jr. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998, 38(2 Pt. 1): 230-9.
44. Jacobs, S., Grussendorf-Conen, E.I., Rosener, I. and Rubben A. Molecular analysis of the effect of topical imiquimod treatment of HPV 2/27/57-induced common warts. Skin Pharmacol Physiol 2004, 17(5): 258-66.
45. Averett, D.R., Fletcher, S.P., Li, W., Webber, S.E. and Appleman, J.R. The pharmacology of endosomal TLR agonists in viral disease. Biochem Soc Trans 2007, 35(Pt. 6): 1468-72.
46. Yan, J., Chen, S.L., Wang, H.N. and Wu, T.X. Meta-analysis of 5% imiquimod and 0.5% podophyllotoxin in the treatment of condylomata acuminata. Dermatology 2006, 213(3): 218-23.
47. Richter, O.N., Petrow, W., Wardelmann, E., Dorn, C., Kupka, M. and Ulrich, U. Bowenoid papulosis of the vulva-immunotherapeutical approach with topical imiquimod. Arch Gynecol Obstet 2003, 268(4): 333-6.
48. Petrow, W., Gerdsen, R., Uerlich, M., Richter, O. and Bieber, T. Successful topical immunotherapy of bowenoid papulosis with imiquimod. Br J Dermatol 2001, 145(6): 1022-3.
49. Goorney, B.P. and Polori, R. A case of Bowenoid papulosis of the penis successfully treated with topical imiquimod cream 5%. Int J STD AIDS 2004, 15(12): 833-5.
50. Loo, W.J. and Holt, P.J. Bowenoid papulosis successfully treated with imiquimod. J Eur Acad Dermatol Venereol 2003, 17(3): 363-5.
51. Godfrey, J.C., Vaughan, M.C. and Williams, J.V. Successful treatment of bowenoid papulosis in a 9-year-old girl with vertically acquired human immunodeficiency virus. Pediatrics 2003, 112(1 Pt. 1): e73-6.
52. Nunes, M.G., Trope, B.M., Cavalcanti, S.M., Oliveira, L.H. and Ramos-e-Silva. Bowenoid papulosis in a patient with AIDS treated with imiquimod: Case report. Acta Dermatovenerol Croat 2004, 12(4): 278-81.
53. Ben, M.L., Mebazaa, A., Euvrard, S. et al. 5% topical imiquimod tolerance in transplant recipients. Dermatology 2007, 215(2): 130-3.
54. Dede, M., Kubar, A., Yenen, M.C. et al. Human papillomavirus-type predict the clinical outcome of imiquimod therapy for women with vulvar condylomata acuminata. Acta Obstet Gynecol Scand 2007, 86(8): 968-72.
55. Maschke, J., Brauns, T.C. and Goos, M. Imiquimod for the topical treatment of focal epithelial hyperplasia (Heck disease) in a child. J Dtsch Dermatol Ges 2004, 2(10): 848-50.
56. Berthelot, C., Dickerson, M.C., Rady, P. et al. Treatment of a patient with epidermodysplasia verruciformis carrying a novel EVER2 mutation with imiquimod. J Am Acad Dermatol 2007, 56(5): 882-6.
57. Baskan, E.B., Tunali, S., Adim, S.B., Turan, A. and Toker, S. A case of epidermodysplasia verruciformis associated with squamous cell carcinoma and Bowen's disease: A therapeutic challenge. J Dermatolog Treat 2006, 17(3): 179-83.
58. Janssen, K., Lucker, G.P., Houwing, R.H. and van, R.R. Epidermodysplasia verruciformis: Unsuccessful therapeutic approach with imiquimod. Int J Dermatol 2007, 46(Suppl. 3): 45-7.
59. Hu, W., Nuovo, G., Willen, M. and Somach, S. Epidermodysplasia verruciformis in two half brothers with HIV infection. J Cutan Med Surg 2004, 8(5): 357-60.
60. Allam, J.P., Erdsach, T., Wenghoefer, M., Bieber, T., Appel, T.R. and Novak, N. Successful treatment of extensive human papillomavirus-associated oral leucoplakia with imiquimod. Br J Dermatol 2008, 158(3): 644-6.
61. Celestin Schartz, N.E., Chevret, S., Paz, C. et al. Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients. J Am Acad Dermatol 2007, Advance publication.
62. Schacker, T.W., Conant, M., Thoming, C., Stanczak, T., Wang, Z. and Smith, M. Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: A phase II, randomized, double-blind, placebo-controlled study. Antimicrob Agents Chemother 2002, 46(10): 3243-8.
63. Lucker, G.P., Speel, E.J., Creytens, D.H. et al. Differences in imiquimod treatment outcome in two patients with bowenoid papulosis containing either episomal or integrated human papillomavirus 16. J Invest Dermatol 2007, 127(3): 727-9.
64. Rosen, T., Harting, M. and Gibson, M. Treatment of Bowen's disease with topical 5% imiquimod cream: Retrospective study. Dermatol Surg 2007, 33(4): 427-31.
65. Jorizzo, J., Dinehart, S., Matheson, R. et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol 2007, 57(2): 265-8.
66. Bath-Hextall, F.J., Perkins, W., Bong, J. and Williams, H.C. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev 2007, 24(1): CD003412.
67. Ahn, S.J., Lee, H.J., Chang, S.E. et al. Case of linear porokeratosis: successful treatment with topical 5% imiquimod cream. J Dermatol 2007, 34(2): 146-7.
68. Micali, G., Nasca, M.R. and De, P.R. Erythroplasia of Queyrat treated with imiquimod 5% cream. J Am Acad Dermatol 2006, 55(5): 901-3.
69. Price, N.M. The treatment of actinic keratoses with a combination of 5-fluorouracil and imiquimod creams. J Drugs Dermatol 2007, 6(8): 778-81.
70. Bukhardt Perez, M.P., Ruiz-Villaverde, R., Naranjo Diaz, M.J., Blasco, M.J. and Naranjo, S.R. Basal cell carcinoma: Treatment with imiquimod. Int J Dermatol 2007, 46(5): 539-42.
71. Geisse, J., Caro, I., Lindholm, J., Golitz, L., Stampone, P. and Owens, M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004, 50(5): 722-33.
72. Gollnick, H., Barona, C.G., Frank, R.G. et al. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: Interim 2-year results from an ongoing 5-year follow-up study in Europe. Eur J Dermatol 2005, 15(5): 374-81.
73. Schiessl, C., Wolber, C., Tauber, M., Offner, F. and Strohal, R. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: Histological and clinical changes, outcome, and follow-up. J Drugs Dermatol 2007, 6(5): 507-13.
74. Eigentler, T.K., Kamin, A., Weide, B.M. et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. J Am Acad Dermatol 2007, 57(4): 616-21.
75. Ezughah, F.I., Dawe, R.S., Ibbotson, S.H. and Fleming, C.J. A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. J Dermatolog Treat 2007, 1-7.
76. Neville, J.A., Williford, P.M. and Jorizzo, J.L. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage. J Drugs Dermatol 2007, 6(9): 910-4.
77. Spenny, M.L., Walford, J., Werchniak, A.E. et al. Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports. Cutis 2007, 79(2): 149-52.
78. Kupfer-Bessaguet, I., Guillet, G., Misery, L., Carre, J.L., Leroy, J.P. and Sassolas, B. Topical imiquimod treatment of lentigo maligna: Clinical and histologic evaluation. J Am Acad Dermatol 2004, 51(4): 635-9.
79. Rajpar, S.F. and Marsden, J.R. Imiquimod in the treatment of lentigo maligna. Br J Dermatol 2006, 155(4): 653-6.
80. Fleming, C.J., Bryden, A.M., Evans, A., Dawe, R.S. and Ibbotson, S.H. A pilot study of treatment of lentigo maligna with 5% imiquimod cream. Br J Dermatol 2004, 151(2): 485-8.
81. Spenny, M.L., Walford, J., Werchniak, A.E. et al. Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports. Cutis 2007, 79(2): 149-52.
82. Micantonio, T., Fargnoli, M.C. and Peris, K. Usefulness of dermoscopy to monitor clinical efficacy of imiquimod treatment for lentigo maligna. Arch Dermatol 2006, 142(4): 530-1.
83. Curiel-Lewandrowski, C., Williams, C.M., Swindells, K.J. et al. Use of in vivo confocal microscopy in malignant melanoma: An aid in diagnosis and assessment of surgical and nonsurgical therapeutic approaches. Arch Dermatol 2004, 140(9): 1127-32.
84. Chapman, M.S., Spencer, S.K. and Brennick, J.B. Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream. Arch Dermatol 2003, 139(7): 943-4.
85. Steinmann, A., Funk, J.O., Schuler, G. and Von Den, D.P. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol 2000, 43(3): 555-6.
86. Palamara, F., Meindl, S., Holcmann, M., Luhrs, P., Stingl, G. and Sibilia, M. Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol 2004, 173(5): 3051-61.
87. Shistik, G., Prakash, A.V., Fenske, N.A. and Glass, L.F. Treatment of locally metastatic melanoma: A novel approach. J Drugs Dermatol 2007, 6(8): 830-2.
88. Utikal, J., Zimpfer, A., Thoelke, A. et al. Complete remission of multiple satellite and in-transit melanoma metastases after sequential treatment with isolated limb perfusion and topical imiquimod. Br J Dermatol 2006, 155(2): 488-91.
89. Wolf, I.H., Smolle, J., Binder, B., Cerroni, L., Richtig, E. and Kerl, H. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol 2003, 139(3): 273-6.
90. Shistik, G., Prakash, A.V., Fenske, N.A. and Glass, L.F. Treatment of locally metastatic melanoma: A novel approach. J Drugs Dermatol 2007, 6(8): 830-2.
91. Green, D.S., Bodman-Smith, M.D., Dalgleish, A.G. and Fischer, M.D. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 2007, 156(2): 337-45.
92. Ugurel, S., Wagner, A., Pfohler, C., Tilgen, W. and Reinhold, U. Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread. Br J Dermatol 2002, 147(3): 621-4.
93. Schon, M.P., Wienrich, B.G., Drewniok, C. et al. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol 2004, 122(5): 1266-76.
94. Hesling, C., D'Incan, M., Mansard, S. et al. In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases. Br J Dermatol 2004, 150(4): 761-7.
95. Somani, N., Martinka, M., Crawford, R.I., Dutz, J.P. and Rivers, J.K. Treatment of atypical nevi with imiquimod 5% cream. Arch Dermatol 2007, 143(3): 379-85.
96. Coors, E.A., Schuler, G. and Von Den, D.P. Topical imiquimod as treatment for different kinds of cutaneous lymphoma. Eur J Dermatol 2006, 16(4): 391-3.
97. Deeths, M.J., Chapman, J.T., Dellavalle, R.P., Zeng, C. and Aeling, J.L. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J Am Acad Dermatol 2005, 52(2): 275-80.
98. Chiam, L.Y. and Chan, Y.C. Solitary plaque mycosis fungoides on the penis responding to topical imiquimod therapy. Br J Dermatol 2007, 156(3): 560-2.
99. Kouba, D.J., Yip, D., Fincher, E.F. and Moy, R.L. Topical imiquimod in the treatment of a long-standing capillary malformation. Br J Dermatol 2007, 157(5): 1071-2.
100. Welsh, O., Olazaran, Z., Gomez, M., Salas, J. and Berman, B. Treatment of infantile hemangiomas with short-term application of imiquimod 5% cream. J Am Acad Dermatol 2004, 51(4): 639-42.
101. Fallah, H., Fischer, G. and Zagarella, S. Pyogenic granuloma in children: Treatment with topical imiquimod. Australas J Dermatol 2007, 48(4): 217-20.
102. Malhotra, A.K., Gupta, S., Khaitan, B.K. and Sharma, V.K. Imiquimod 5% cream for the prevention of recurrence after excision of presternal keloids. Dermatology 2007, 215(1): 63-5.
103. Berman, B. and Villa, A. Imiquimod 5% cream for keloid management. Dermatol Surg 2003, 29(10): 1050-1.
104. Berman, B. and Kaufman, J. Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J Am Acad Dermatol 2002, 47(4 Suppl.): S209-11.
105. Martin-Garcia, R.F. and Busquets, A.C. Postsurgical use of imiquimod 5% cream in the prevention of earlobe keloid recurrences: Results of an open-label, pilot study. Dermatol Surg 2005, 31(11 Pt. 1): 1394-8.
106. Stashower, M.E. Successful treatment of earlobe keloids with imiquimod after tangential shave excision. Dermatol Surg 2006, 32(3): 380-6.
107. Gul, U., Gonul, M., Cakmak, S.K., Kilic, A. and Demiriz, M. A case of generalized discoid lupus erythematosus: Successful treatment with imiquimod cream 5%. Adv Ther 2006, 23(5): 787-92.
108. Gerdsen, R., Wenzel, J., Uerlich, M., Bieber, T. and Petrow, W. Successful treatment of chronic discoid lupus erythematosus of the scalp with imiquimod. Dermatology 2002, 205(4): 416-8.
109. Arevalo, I., Tulliano, G., Quispe, A. et al. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis 2007, 44(12): 1549-54.
110. Letada, P.R., Sparling, J.D. and Norwood, C. Imiquimod in the treatment of alopecia universalis. Cutis 2007, 79(2): 138-40.
111. D'Ovidio, R., Claudatus, J. and Di, P.T. Ineffectiveness of imiquimod therapy for Alopecia Totalis/Universalis. J Eur Acad Dermatol Venereol 2002, 16(4): 416-7.